2025-07-08 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, presented in a report format.

## Johnson & Johnson (JNJ) Stock Analysis Report

**Ticker:** JNJ
**Company Name:** Johnson & Johnson
**Description:** Johnson & Johnson is a global healthcare company that develops, manufactures, and sells a broad range of products in the areas of pharmaceuticals, medical devices, and consumer health.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 14.93%
*   **VOO Cumulative Return:** 95.42%
*   **Absolute Performance Difference:** -80.49% (JNJ significantly underperformed VOO)
*   **Deviation Analysis:**
    *   **Max Deviation:** 20.0
    *   **Min Deviation:** -83.0
    *   **Current Deviation:** -80.49
    *   **Relative Deviation:** 2.1 (This indicates JNJ's underperformance is near its worst historical levels relative to VOO within the analyzed period).

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta | Cap(B) |
|------------|---------|---------|--------|------|--------|
| 2015-2017  | 28.0%   | 56.1%   | -1.0%  | -0.0 | 334.1  |
| 2016-2018  | 8.0%    | 56.6%   | -10.0% | 0.0  | 308.6  |
| 2017-2019  | 18.0%   | 56.6%   | -12.0% | 0.7  | 348.8  |
| 2018-2020  | 12.0%   | 59.2%   | -8.0%  | 0.3  | 376.3  |
| 2019-2021  | 32.0%   | 59.6%   | -16.0% | 0.2  | 409.1  |
| 2020-2022  | 7.0%    | 61.4%   | 5.0%   | 0.2  | 422.4  |
| 2021-2023  | -15.0%  | 61.4%   | -33.0% | 0.4  | 374.8  |
| 2022-2024  | -35.0%  | 61.4%   | -61.0% | 0.3  | 345.8  |
| 2023-2025  | -12.0%  | 70.1%   | -60.0% | 0.2  | 373.1  |

**Analysis:**

*   **Significant Underperformance:** JNJ has significantly underperformed the S&P 500 (VOO) based on cumulative returns.
*   **Alpha Analysis:** The Alpha values are consistently negative for most periods, indicating JNJ has generally underperformed relative to its risk-adjusted expected return based on the S&P 500. The negative Alpha values are particularly pronounced in more recent periods.
*   **Beta Analysis:** The Beta values are low, suggesting JNJ's price is not highly correlated with the S&P 500.
*   **MDD (Maximum Drawdown):** High MDD values indicate substantial potential losses over the analyzed periods.

### 2. Recent Stock Price Movements

*   **Current Price:** 156.00999450683594
*   **Last Market Data:**
    *   Price: 155.02
    *   Previous Close: 156.01
    *   Change: -0.63
*   **Moving Averages:**
    *   5-day MA: 154.545
    *   20-day MA: 153.9017
    *   60-day MA: 153.7569

**Analysis:**

*   **Recent Decline:** The stock closed lower than the previous day, and there is a slight overall price decrease.
*   **Moving Average Convergence:** The 5-day moving average is above the 20-day and 60-day moving averages, which could suggest a short-term upward trend. However, the differences are small, indicating potential consolidation.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 47.8448 (Neutral)
*   **PPO:** 0.2447
*   **Hybrid Signal:** cash_1%_Buy 80% of cash (21 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Deviation Change:** -4.2 (Negative: Short-term Decline)
*   **Expected Return (%):** -1391.2 (Very Negative)

**Analysis:**

*   **MRI:** The MRI indicates a low-risk environment, which suggests lower market volatility.
*   **RSI:** The RSI is near the middle range, indicating neither overbought nor oversold conditions.
*   **PPO:** The PPO (Percentage Price Oscillator) value of 0.2447 suggests that the short-term moving average is slightly above the long-term moving average. This is generally considered a mildly bullish sign.
*   **Hybrid Signal:** The signal suggests a buy with caution, indicating some potential but with a risk management approach (keeping cash available).
*   **20-day Deviation Change:** The negative change confirms a recent downward trend in performance relative to VOO.
*   **Expected Return:** The extremely negative expected return should be interpreted with caution. It might be related to specific model assumptions or data limitations and shouldn't be taken as a precise prediction.

### 4. Recent News & Significant Events

*   **[2025-07-06]:** Major business developments, regulatory changes, or market events are affecting Johnson & Johnson (JNJ).
*   **[2025-07-07]:** Analysts are discussing Johnson & Johnson's (JNJ) recent performance and outlook within the context of industry trends and global economic factors.
*   **[2025-07-05]:** Johnson & Johnson (JNJ)'s stock has shown notable volatility due to recent news, earnings reports, or executive actions.
*   **[2025-07-08]:** Market experts highlight both risks and opportunities for Johnson & Johnson (JNJ), advising investors to monitor recent news and company announcements.

**Analysis:**

Recent news indicates a dynamic environment for JNJ, with volatility and significant events potentially influencing the stock's performance.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-04-23   | 4.57 | 21.89 B$    |
| 2024-10-23   | 1.12 | 22.47 B$    |
| 2024-07-25   | 1.95 | 22.45 B$    |
| 2024-05-01   | 1.35 | 21.38 B$    |
| 2025-04-23   | 1.35 | 21.38 B$    |

**Analysis:**

*   **Inconsistent EPS:** EPS (Earnings Per Share) has fluctuated significantly over the reported quarters. The recent value of 4.57 stands out as particularly high compared to other periods.
*   **Stable Revenue:** Revenue has remained relatively stable, hovering around $21-22 billion.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |
| 2024-06-30   | $22.45B   | 69.40%        |
| 2024-03-31   | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-03-31   | $78.11B   | 14.08%   |
| 2024-12-31   | $71.49B   | 4.80%    |
| 2024-09-30   | $70.16B   | 3.84%    |
| 2024-06-30   | $71.54B   | 6.55%    |
| 2024-03-31   | $70.02B   | 4.65%    |

**Analysis:**

*   **Profit Margin:** Profit margins have been high, ranging from 66.40% to 69.55%, indicating strong profitability. However, there's a recent decrease.
*   **Equity:** Equity has generally increased over the analyzed period, suggesting a strengthening financial position.
*   **ROE:** ROE (Return on Equity) has fluctuated. The most recent ROE is significantly higher than previous periods.

### 7. Summary Analysis

Johnson & Johnson (JNJ) has significantly underperformed the S&P 500 (VOO) over the analyzed period. While the company maintains strong profitability (high-profit margins) and a low-risk market environment, recent indicators suggest a short-term decline. Revenue has been stable, but EPS has fluctuated. The recent news indicates significant events affecting the company, which may contribute to the observed volatility. The technical indicators show a neutral RSI and a buy signal with caution, which aligns with the low-risk MRI. The high recent ROE contrasts with a negative expected return, which suggests caution is warranted when interpreting predictive metrics. Overall, the analysis shows a company with financial stability but facing performance challenges and market uncertainty.
